SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Seong Hee Kang, Hyung Joon Yim, Hae Rim Kim, Keunhee Kang, Sang Jun Suh, Hyun Jung Lee, Eileen L. Yoon, Ji Hoon Kim, Yeon Seok Seo, Jong Eun Yeon, Kwan Soo Byun, Comparison of Lamivudine Plus Adefovir Therapy Versus Entecavir With or Without Adefovir Therapy for Adefovir-resistant Chronic Hepatitis B, Journal of Clinical Gastroenterology, 2014, 1

    CrossRef

  2. 2
    Yoo-Kyung Cho, Xiu-Ji Cui, Seung Uk Jeong, Byung-Cheol Song, Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B, Antiviral Research, 2014, 112, 8

    CrossRef

  3. 3
    M. Rybicka, P. Stalke, K.P. Bielawski, Dynamics of hepatitis B virus quasispecies heterogeneity in association with nucleos(t)ide analogue treatment determined by MALDI-TOF MS, Clinical Microbiology and Infection, 2014,

    CrossRef

  4. 4
    Xiaohong Wang, Changjiang Zhang, Yan Zhu, Yulin Xiong, Yuming Wang, Efficacy of 2years of entecavir plus adefovir therapy in patients with chronic hepatitis B who had failed on prior nucleos(t)ide analog treatment, Antiviral Research, 2014, 103, 71

    CrossRef

  5. 5
    Teng Zeng, Hua Xu, Jun-Ying Liu, Yu Lei, Shan Zhong, Zhi Zhou, Entecavir plus adefovir combination therapy versus lamivudine add-on adefovir for lamivudine-resistant chronic hepatitis B: A meta-analysis, The Journal of Clinical Pharmacology, 2014, 54, 9
  6. 6
    J. Fan, Y. Wang, H. Xiong, X. Guo, Y.-c. Cheng, Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility, Journal of General Virology, 2014, 95, Pt_11, 2523

    CrossRef

  7. 7
    Emily Funk, Shyam Kottilil, Bruce Gilliam, Rohit Talwani, Tickling the TLR7 to cure viral hepatitis, Journal of Translational Medicine, 2014, 12, 1, 129

    CrossRef

  8. 8
    Erik De Clercq, A Cutting-Edge View on the Current State of Antiviral Drug Development, Medicinal Research Reviews, 2013, 33, 6
  9. 9
    G.-C. Park, S. Hwang, C.-S. Ahn, K.-H. Kim, D.-B. Moon, T.-Y. Ha, G.-W. Song, D.-H. Jung, Y.W. Shin, S.-H. Kim, K.-H. Chang, J.-M. Namgoong, C.-S. Park, H.-W. Park, Y.-H. Park, S.-H. Kang, B.-H. Jung, S.-G. Lee, Analysis of S Gene Mutation of the Hepatitis B Virus in Adult Liver Transplant Recipients Showing Resistance to Hepatitis B Immunoglobulin Therapy, Transplantation Proceedings, 2013, 45, 8, 3047

    CrossRef

  10. 10
    Mi Sung Park, Beom Kyung Kim, Kyung Sik Kim, Ja Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Oidov Baartarkhuu, Kwang Hyub Han, Chae Yoon Chon, Sang Hoon Ahn, Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B, Clinical and Molecular Hepatology, 2013, 19, 1, 29

    CrossRef

  11. 11
    Christophe Rodriguez, Stéphane Chevaliez, Paul Bensadoun, Jean-Michel Pawlotsky, Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing, Hepatology, 2013, 58, 3
  12. 12
    J. Peveling-Oberhag, E. Herrmann, B. Kronenberger, H. Farnik, S. Susser, C. Sarrazin, S. Zeuzem, W.-P. Hofmann, Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs, Journal of Viral Hepatitis, 2013, 20, 4
  13. 13
    Yan Zhang, Song He, Qing-Ling Li, Jin-Jun Guo, Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy, Virus Research, 2013, 177, 2, 156

    CrossRef

  14. 14
    Xiao-Lin Deng, Qing-Ling Li, Jin-Jun Guo, Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy, Virus Genes, 2013, 47, 1, 1

    CrossRef

  15. 15
    Dwayne M. Baxa, Ashish D. Thekdi, Alicia Golembieski, Prashant V. Krishnan, Omar Sharif, Anne Kizy, Lynne Shetron-Rama, John Jovanovich, Brandi J. Chappell, Andrea Snow-Lampart, Katyna Borroto-Esoda, Stuart C. Gordon, Evaluation of anti-HBV drug resistant mutations among patients with acute symptomatic hepatitis B in the United States, Journal of Hepatology, 2013, 58, 2, 212

    CrossRef

  16. 16
    Sara A Healy, Sonia Gupta, Ann J Melvin, HIV/HBV coinfection in children and antiviral therapy, Expert Review of Anti-infective Therapy, 2013, 11, 3, 251

    CrossRef

  17. 17
    Soon Sun Kim, Sung Won Cho, Soo-Ok Kim, Sun Pyo Hong, Jae Youn Cheong, Multidrug-resistant hepatitis B virus resulting from sequential monotherapy with lamivudine, adefovir, and entecavir: Clonal evolution during lamivudine plus adefovir therapy, Journal of Medical Virology, 2013, 85, 1
  18. You have free access to this content18
    Fabien Zoulim, Stephen Locarnini, Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance, Liver International, 2013, 33,
  19. 19
    Hyung Joon Yim, Seong Gyu Hwang, Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade, Clinical and Molecular Hepatology, 2013, 19, 3, 195

    CrossRef

  20. 20
    Do Young Kim, Hye Young Chang, Sun Min Lim, Seung Up Kim, Jun Yong Park, Ja Kyung Kim, Kwan Sik Lee, Kwang-Hyub Han, Chae Yoon Chon, Sang Hoon Ahn, Quasispecies and Pre-Existing Drug-Resistant Mutations of Hepatitis B Virus in Patients with Chronic Hepatitis B, Gut and Liver, 2013, 7, 3, 329

    CrossRef

  21. 21
    Yuri Cho, Dong Hyeon Lee, Kwang Hyun Chung, Eunhyo Jin, Jeong-Hoon Lee, Eun Ju Cho, Su Jong Yu, Jin Wook Kim, Sook Hyang Jeong, Jung-Hwan Yoon, Hyo-Suk Lee, Chung Yong Kim, Yoon Jun Kim, The Efficacy of Adefovir Plus Entecavir Combination Therapy in Patients with Chronic Hepatitis B Refractory to Both Lamivudine and Adefovir, Digestive Diseases and Sciences, 2013, 58, 5, 1363

    CrossRef

  22. 22
    S.-Y. Ko, H.-B. Oh, C.-W. Park, H. C. Lee, J.-E. Lee, Analysis of hepatitis B virus drug-resistant mutant haplotypes by ultra-deep pyrosequencing, Clinical Microbiology and Infection, 2012, 18, 10
  23. 23
    Eleftherios Michailidis, Karen A. Kirby, Atsuko Hachiya, Wangdon Yoo, Sun Pyo Hong, Soo-Ok Kim, William R. Folk, Stefan G. Sarafianos, Antiviral therapies: Focus on hepatitis B reverse transcriptase, The International Journal of Biochemistry & Cell Biology, 2012, 44, 7, 1060

    CrossRef

  24. 24
    KASL Clinical Practice Guidelines: Management of chronic hepatitis B, Clinical and Molecular Hepatology, 2012, 18, 2, 109

    CrossRef

  25. 25
    Chang Young Son, Han Jak Ryu, Jung Min Lee, Sang Hoon Ahn, Do Young Kim, Myoung Ha Lee, Kwang Hyub Han, Chae Yoon Chon, Jun Yong Park, Lamivudine plus adefovir vs. entecavir in HBeAg-positive hepatitis B with sequential treatment failure of lamivudine and adefovir, Liver International, 2012, 32, 7
  26. 26
    Fabien Zoulim, Stephen Locarnini, Management of treatment failure in chronic hepatitis B, Journal of Hepatology, 2012, 56, S112

    CrossRef

  27. 27
    Yanwei Zhong, Jiyun Lv, Jin Li, Xiaoyan Xing, Hua Zhu, Heling Su, Li Chen, Xianzhi Zhou, Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B, Antiviral Research, 2012, 93, 1, 185

    CrossRef

  28. 28
    Cheng Wang, Rong Fan, Jian Sun, Jinlin Hou, Prevention and management of drug resistant hepatitis B virus infections, Journal of Gastroenterology and Hepatology, 2012, 27, 9
  29. 29
    M. G. Ghany, J. J. Feld, X. Zhao, T. Heller, E. Doo, Y. Rotman, P. Nagabhyru, C. Koh, D. E. Kleiner, E. C. Wright, T. J. Liang, J. H. Hoofnagle, Randomised clinical trial: the benefit of combination therapy with adefovir and lamivudine for chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2012, 35, 9
  30. 30
    Uma Devi, Stephen Locarnini, Role of Resistance Testing During Oral Antiviral Therapy of Chronic Hepatitis B, Current Hepatitis Reports, 2012, 11, 2, 55

    CrossRef

  31. 31
    Gaetano Scotto, Giovanna D'Addiego, Adele Giammario, Francesca Campanale, Vincenzina Fazio, Tenofovir plus entecavir as rescue therapy for multidrug-resistant chronic hepatitis B, Liver International, 2012, 32, 1
  32. 32
    Moon Seok Choi, Dong Hyun Sinn, Su-A Kim, Yil Seob Lee, Won Choi, Seung Woon Paik, The Clinical and Laboratory Characteristics of Patients with Chronic Hepatitis B Using Current or Past Antiviral Therapy in Korea: A Multi-Center, Nation-Wide, Cross-Sectional Epidemiologic Study, Gut and Liver, 2012, 6, 2, 241

    CrossRef

  33. 33
    Chien-Hung Chen, Jing-Houng Wang, Sheng-Nan Lu, Tsung-Hui Hu, Chao-Hung Hung, Min-Hui Chang, Chi-Sin Changchien, Chuan-Mo Lee, Characteristics of adefovir resistance in patients with or without lamivudine-resistant hepatitis B virus treated with adefovir: a 4-year experience, Liver International, 2011, 31, 2
  34. 34
    Mashu Aizawa, Akihito Tsubota, Kiyotaka Fujise, Keiko Tatsuzawa, Midori Kono, Sadayori Hoshina, Hisao Tajiri, Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients, Journal of Medical Virology, 2011, 83, 6
  35. 35
    Hidehiro Kamezaki, Tatsuo Kanda, Shuang Wu, Shingo Nakamoto, Makoto Arai, Hitoshi Maruyama, Keiichi Fujiwara, Fumio Imazeki, Osamu Yokosuka, Emergence of entecavir-resistant mutations in nucleos(t)ide-naive Japanese patients infected with hepatitis B virus: Virological breakthrough is also dependent on adherence to medication, Scandinavian Journal of Gastroenterology, 2011, 46, 9, 1111

    CrossRef

  36. 36
    Shuang Wu, Fumio Imazeki, Fuat Kurbanov, Kenichi Fukai, Makoto Arai, Tatsuo Kanda, Yutaka Yonemitsu, Yasuhito Tanaka, Masashi Mizokami, Osamu Yokosuka, Evolution of hepatitis B genotype C viral quasi-species during hepatitis B e antigen seroconversion, Journal of Hepatology, 2011, 54, 1, 19

    CrossRef

  37. 37
    Ying-Zi Tang, Lin Liu, Mei-Min Pan, Yu-Ming Wang, Guo-Hong Deng, Evolutionary pattern of full hepatitis B virus genome during sequential nucleos(t)ide analog therapy, Antiviral Research, 2011, 90, 3, 116

    CrossRef

  38. 38
    Y. Liu, C. Wang, Y. Zhong, X. Li, J. Dai, X. Ren, Z. Xu, L. Li, Z. Yao, D. Ji, L. Wang, L. Zhang, V. W. -S. Wong, F. Zoulim, D. Xu, Genotypic resistance profile of hepatitis B virus (HBV) in a large cohort of nucleos(t)ide analogue-experienced Chinese patients with chronic HBV infection, Journal of Viral Hepatitis, 2011, 18, 4
  39. 39
    Hellan Kwon, Anna S. Lok, Hepatitis B therapy, Nature Reviews Gastroenterology & Hepatology, 2011,

    CrossRef

  40. 40
    Lihui Deng, Hong Tang, Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites, Hepatology Research, 2011, 41, 11
  41. You have free access to this content41
    Fabien Zoulim, Hepatitis B virus resistance to antiviral drugs: where are we going?, Liver International, 2011, 31,
  42. 42
    Olivier Lada, Tarik Asselah, Patrick Marcellin, Hepatitis B virus Resistance to Antivirals : Diagnosis and Management, Current Hepatitis Reports, 2011, 10, 4, 244

    CrossRef

  43. 43
    Alyson N. Fox, Norah A. Terrault, Individualizing hepatitis B infection prophylaxis in liver transplant recipients, Journal of Hepatology, 2011, 55, 3, 507

    CrossRef

  44. 44
    M. S. Kwak, J. W. Choi, J. S. Lee, K. A. Kim, J. H. Suh, Y. S. Cho, S. Y. Won, B. K. Park, C. K. Lee, Long-term efficacy of entecavir therapy in chronic hepatitis B patients with antiviral resistance to lamivudine and adefovir, Journal of Viral Hepatitis, 2011, 18, 10
  45. 45
    Shin Hwang, Chul-Soo Ahn, Gi-Won Song, Ki-Hun Kim, Deok-Bog Moon, Heung-Bum Oh, Young-Suk Lim, Han Chu Lee, Tae-Yong Ha, Dong-Hwan Jung, Young-Hwa Chung, Sung-Gyu Lee, Posttransplantation prophylaxis with primary high-dose hepatitis B immunoglobulin monotherapy and complementary preemptive antiviral add-on, Liver Transplantation, 2011, 17, 4
  46. 46
    J. Sun, J.-L. Hou, Q. Xie, X.-H. Li, J.-M. Zhang, Y.-M. Wang, H. Wang, J.-Y. Lai, S.-J. Chen, J.-D. Jia, J.-F. Sheng, H. L. Y. Chan, J.-F. Wang, M. K. K. Li, M. Jiang, M. Popescu, J. J. Y. Sung, Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance, Alimentary Pharmacology & Therapeutics, 2011, 34, 4
  47. 47
    Yong-Zhong Wang, Jun-Hua Xiao, Long-Gen Liu, Chun-Yan Ye, Hong-Yu Shen, Tian-Min Xu, Ke-Zhuan Zhu, Simultaneous detection of hepatitis B virus genotypes and mutations associated with resistance to lamivudine, adefovir, and telbivudine by the polymerase chain reaction-ligase detection reaction, The Brazilian Journal of Infectious Diseases, 2011, 15, 6, 560

    CrossRef

  48. 48
    Irene N Rapti, Stephanos J Hadziyannis, Treatment of special populations with chronic hepatitis B infection, Expert Review of Gastroenterology & Hepatology, 2011, 5, 3, 323

    CrossRef

  49. 49
    Zhihui Xu, Yan Liu, Teng Xu, Li Chen, Lanlan Si, Yao Wang, Xiaoqiang Ren, Yanwei Zhong, Jingmin Zhao, Dongping Xu, Acute hepatitis B infection associated with drug-resistant hepatitis B virus, Journal of Clinical Virology, 2010, 48, 4, 270

    CrossRef

  50. 50
    Lynne Strasfeld, Sunwen Chou, Antiviral Drug Resistance: Mechanisms and Clinical Implications, Infectious Disease Clinics of North America, 2010, 24, 2, 413

    CrossRef

  51. 51
    Lynne Strasfeld, Sunwen Chou, Antiviral Drug Resistance: Mechanisms and Clinical Implications, Infectious Disease Clinics of North America, 2010, 24, 3, 809

    CrossRef

  52. 52
    A. Kahloun, M. Bourlière, F. Zoulim, Bithérapie par analogues dans le traitement de l’hépatite chronique B : de novo ou en cas d’échec, Gastroentérologie Clinique et Biologique, 2010, 34, S126

    CrossRef

  53. 53
    Bao-Ming Liu, Tong Li, Jie Xu, Xiao-Guang Li, Jian-Ping Dong, Ping Yan, Jing-Xian Yang, Ling Yan, Zhi-Yong Gao, Wen-Peng Li, Xie-Wen Sun, Yu-Hua Wang, Xiu-Juan Jiao, Chun-Sheng Hou, Hui Zhuang, Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naïve Chinese patients, Antiviral Research, 2010, 85, 3, 512

    CrossRef

  54. 54
    Stephen Locarnini, Scott Bowden, Drug Resistance in Antiviral Therapy, Clinics in Liver Disease, 2010, 14, 3, 439

    CrossRef

  55. 55
    Chien-Hung Chen, Chuan-Mo Lee, Wei-Chih Tung, Jing-Houng Wang, Chao-Hung Hung, Tsung-Hui Hu, Jyh-Chwan Wang, Sheng-Nan Lu, Chi-Sin Changchien, Evolution of full-length HBV sequences in chronic hepatitis B patients with sequential lamivudine and adefovir dipivoxil resistance, Journal of Hepatology, 2010, 52, 4, 478

    CrossRef

  56. 56
    Byeong Uk Kim, Ja Chung Goo, Byeong Chul Park, Soo Ok Kim, Sun Pyo Hong, Jee In Jeong, Hee Bok Chae, Seon Mee Park, Sei Jin Youn, Genotypic resistance to entecavir in chronic hepatitis B patients, The Korean Journal of Hepatology, 2010, 16, 2, 147

    CrossRef

  57. 57
    Nae-Yun Heo, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Dong Jin Suh, Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir, Journal of Hepatology, 2010, 53, 3, 449

    CrossRef

  58. 58
    Robert Perrillo, Sleisenger and Fordtran's Gastrointestinal and Liver Disease, 2010,

    CrossRef

  59. 59
    MARGARET JAMES KOZIEL, CHLOE LYNNE THIO, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 2010,

    CrossRef

  60. 60
    R. Idilman, S. Kaymakoglu, F. Oguz Onder, E. Ahishali, M. Bektas, K. Cinar, B. Pınarbasi, S. Karayalcin, S. Badur, Y. Cakaloglu, A. Mithat Bozdayi, H. Bozkaya, A. Ökten, C. Yurdaydin, A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients, Journal of Viral Hepatitis, 2009, 16, 4
  61. 61
    Hyun Joo Suh, Moon Kyung Park, Hyang Ie Lee, Geum Yeon Gwak, Kwang Cheol Koh, Seung Woon Paik, Byung Chul Yoo, Joon Hyeok Lee, Antiviral Efficacy of Lamivudine/Adefovir Combination Therapy in Chronic Hepatitis B Patients with Resistance to Lamivudine and Adefovir Consecutively, The Korean Journal of Gastroenterology, 2009, 53, 5, 305

    CrossRef

  62. 62
    Marc G. Ghany, Edward C. Doo, Antiviral resistance and hepatitis B therapy, Hepatology, 2009, 49, S5
  63. 63
    Norah A. Terrault, Benefits and risks of combination therapy for hepatitis B, Hepatology, 2009, 49, S5
  64. 64
    Fen Ji, Li Zhou, Sufang Ma, Feifei Li, Huiguo Ding, Changqing Zeng, Dynamic changes of HBV quasispecies and deletion patterns in a chronic hepatitis B patient, Journal of Medical Virology, 2009, 81, 9
  65. 65
    Jin-Jun Guo, Qing-Ling Li, Xiao-Feng Shi, Da-Zhi Zhang, Ai-Zhong Zeng, Tao Feng, Ai-Long Huang, Dynamics of hepatitis B virus resistance to entecavir in a nucleoside/nucleotide-naïve patient, Antiviral Research, 2009, 81, 2, 180

    CrossRef

  66. 66
    Li Chen, Qian Zhang, De-min Yu, Mo-bin Wan, Xin-xin Zhang, Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy, Journal of Hepatology, 2009, 50, 5, 895

    CrossRef

  67. 67
    Ju Hyun Shim, Dong Jin Suh, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone, Hepatology, 2009, 50, 4
  68. 68
    Feifei Wang, Honghai Wang, Hongbo Shen, Chengyan Meng, Xinhua Weng, Wenhong Zhang, Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues, Clinical Therapeutics, 2009, 31, 2, 360

    CrossRef

  69. 69
    Fabien Zoulim, Stephen Locarnini, Hepatitis B Virus Resistance to Nucleos(t)ide Analogues, Gastroenterology, 2009, 137, 5, 1593

    CrossRef

  70. 70
    Watcharasak Chotiyaputta, Anna S. F. Lok, Hepatitis B virus variants, Nature Reviews Gastroenterology & Hepatology, 2009, 6, 8, 453

    CrossRef

  71. You have free access to this content71
    Daniel J. Tenney, Ronald E. Rose, Carl J. Baldick, Kevin A. Pokornowski, Betsy J. Eggers, Jie Fang, Michael J. Wichroski, Dong Xu, Joanna Yang, Richard B. Wilber, Richard J. Colonno, Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapy, Hepatology, 2009, 49, 5
  72. 72
    Samad Amini-Bavil-Olyaee, Ulf Herbers, Seyed Reza Mohebbi, Farzaneh Sabahi, Mohammad Reza Zali, Tom Luedde, Christian Trautwein, Frank Tacke, Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome, Journal of Hepatology, 2009, 51, 4, 647

    CrossRef

  73. 73
    Man-Fung Yuen, James Fung, Danny Ka-Ho Wong, Ching-Lung Lai, Prevention and management of drug resistance for antihepatitis B treatment, The Lancet Infectious Diseases, 2009, 9, 4, 256

    CrossRef

  74. 74
    Bulent Degertekin, Munira Hussain, Jessica Tan, Kelly Oberhelman, Anna S. Lok, Sensitivity and accuracy of an updated line probe assay (HBV DR v.3) in detecting mutations associated with hepatitis B antiviral resistance, Journal of Hepatology, 2009, 50, 1, 42

    CrossRef

  75. 75
    Ri-Cheng Mao, You-Kuan Yin, Yan-Li Qin, Xiang-Hui Wu, Xin-Hua Weng, Ji-Ming Zhang, Mengji Lu, Spontaneous HBeAg seroconversion and loss of hepatitis B virus DNA after acute flare due to development of drug resistant mutants during entecavir monotherapy, Hepatology Research, 2009, 39, 1
  76. 76
    Masumi Fujimoto, Tatsuki Ichikawa, Kazuhiko Nakao, Hisamitsu Miyaaki, Hidetaka Shibata, Susumu Eguchi, Mitsuhisa Takatsuki, Shinya Nagaoka, Hiroshi Yatsuhashi, Takashi Kanematsu, Katsumi Eguchi, The Significance of Enzyme Immunoassay for the Assessment of Hepatitis B Virus Core-Related Antigen following Liver Transplantation, Internal Medicine, 2009, 48, 18, 1577

    CrossRef

  77. 77
    Anil Seetharam, Mauricio Lisker-Melman, Treatment of chronic hepatitis B: Are we ready for combination therapy?, Current Gastroenterology Reports, 2009, 11, 1, 22

    CrossRef

  78. 78
    C. Fournier, F. Zoulim, Associations thérapeutiques dans la prise en charge des hépatites chroniques B, Gastroentérologie Clinique et Biologique, 2008, 32, 1, S42

    CrossRef

  79. 79
    Samreen Ijaz, Catherine Arnold, Samir Dervisevic, Jana Mechurova, Nick Tatman, Richard S. Tedder, Nikolai V. Naoumov, Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy, Journal of Medical Virology, 2008, 80, 7
  80. 80
    Hyung Joon Kim, Entecavir 1 mg therapy for lamivudine-refractory chronic hepatitis B, The Korean Journal of Hepatology, 2008, 14, 3, 411

    CrossRef

  81. 81
    Ioannis Goulis, George N Dalekos, Entecavir monotherapy for lamivudine-refractory chronic hepatitis B, Expert Review of Anti-infective Therapy, 2008, 6, 6, 855

    CrossRef

  82. 82
    Cihan Yurdaydin, Entecavir: a step forward in combating hepatitis B disease, Expert Opinion on Pharmacotherapy, 2008, 9, 17, 3095

    CrossRef

  83. 83
    Hyung Joon Yim, Hepatitis B virus genetic diversity and mutant, The Korean Journal of Hepatology, 2008, 14, 4, 446

    CrossRef

  84. 84
    Fabien Zoulim, Robert Perrillo, Hepatitis B: Reflections on the current approach to antiviral therapy, Journal of Hepatology, 2008, 48, S2

    CrossRef

  85. 85
    Anna S. F. Lok, How to diagnose and treat hepatitis B virus antiviral drug resistance in the liver transplant setting, Liver Transplantation, 2008, 14, S2
  86. 86
    Stéphanie Villet, Christian Pichoud, Gaëtan Billioud, Luc Barraud, Sandra Durantel, Christian Trépo, Fabien Zoulim, Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure, Journal of Hepatology, 2008, 48, 5, 747

    CrossRef

  87. 87
    Silvia Gaia, Valeria Barbon, Antonina Smedile, Antonella Olivero, Silvia Carenzi, Marco Lagget, Carlo Alessandria, Mario Rizzetto, Alfredo Marzano, Lamivudine-resistant chronic hepatitis B: An observational study on adefovir in monotherapy or in combination with lamivudine, Journal of Hepatology, 2008, 48, 4, 540

    CrossRef

  88. 88
    N. A. Singh, N. Reau, Management of hepatitis B virus, Journal of Antimicrobial Chemotherapy, 2008, 62, 2, 224

    CrossRef

  89. 89
    Fabien Zoulim, Sylvie Radenne, Christian Ducerf, Management of patients with decompensated hepatitis B virus associated cirrhosis, Liver Transplantation, 2008, 14, S2
  90. 90
    Bulent Degertekin, Anna S. Lok, Monitoring antiviral resistance in patients receiving nucleos(t)ide analog therapies for hepatitis B: Which method should be used?, Journal of Hepatology, 2008, 48, 6, 892

    CrossRef

  91. 91
    Brent E. Korba, Abigail B. Montero, Kristine Farrar, Karen Gaye, Sampa Mukerjee, Marc S. Ayers, Jean-François Rossignol, Nitazoxanide, tizoxanide and other thiazolides are potent inhibitors of hepatitis B virus and hepatitis C virus replication, Antiviral Research, 2008, 77, 1, 56

    CrossRef

  92. 92
    Mark A Feitelson, Marcia M Clayton, Helena MGPV Reis, Guoyi Wu, Eva Ping Lu, Pharmacotherapy of chronic viral hepatitis and hepatocellular carcinoma, Expert Opinion on Pharmacotherapy, 2008, 9, 13, 2233

    CrossRef

  93. 93
    Patrick TF. Kennedy, Natalie Phillips, Jaya Chandrasekhar, Ruth Jacobs, Michael Jacobs, Geoffrey Dusheiko, Potential and limitations of lamivudine monotherapy in chronic hepatitis B: evidence from genotyping, Liver International, 2008, 28, 5
  94. 94
    Jessica Tan, Bulent Degertekin, Stephen N. Wong, Munira Husain, Kelly Oberhelman, Anna S.F. Lok, Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations, Journal of Hepatology, 2008, 48, 3, 391

    CrossRef

  95. 95
    Won Hyeok Choe, So Young Kwon, Byung Kook Kim, Soon Young Ko, Jong Eun Yeon, Kwan Soo Byun, Gyun-Hwan Kim, Chang Hong Lee, Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis, Liver International, 2008, 28, 6
  96. 96
    Jae Hyeon Moon, Mong Cho, Ki Tae Yoon, Jung Ho Bae, Jeong Heo, Gwang Ha Kim, Dae Hwan Kang, Geun Am Song, The efficacy of adefovir dipivoxil monotherapy and the incidence of genotypic resistance to adefovir dipivoxil in patients with lamivudine-resistant chronic hepatitis B infection, The Korean Journal of Hepatology, 2008, 14, 4, 503

    CrossRef

  97. 97
    Yu-ming WANG, Lin LIU, The role of viral mutation in the pathogenesis of chronic viral hepatitis, Virologica Sinica, 2008, 23, 2, 132

    CrossRef

  98. 98
    G. Carosi, M. Rizzetto, Treatment of chronic hepatitis B: Recommendations from an Italian workshop, Digestive and Liver Disease, 2008, 40, 8, 603

    CrossRef

  99. 99
    Anna S. Lok, Fabien Zoulim, Stephen Locarnini, Angeline Bartholomeusz, Marc G. Ghany, Jean-Michel Pawlotsky, Yun-Fan Liaw, Masashi Mizokami, Carla Kuiken, Antiviral drug-resistant HBV: Standardization of nomenclature and assays and recommendations for management, Hepatology, 2007, 46, 1
  100. 100
    Claire Fournier, Fabien Zoulim, Antiviral Therapy of Chronic Hepatitis B: Prevention of Drug Resistance, Clinics in Liver Disease, 2007, 11, 4, 869

    CrossRef

  101. 101
    F. Zoulim, M. Buti, A. S. Lok, Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?, Journal of Viral Hepatitis, 2007, 14,
  102. 102
    Anna S. F. Lok, Brian J. McMahon, Chronic hepatitis B, Hepatology, 2007, 45, 2
  103. 103
    George Lau, Patrick Marcellin, Marion Peters, Chronic hepatitis B: a global health problem requiring coherent worldwide treatment strategies, Hepatology International, 2007, 1, 2, 316

    CrossRef

  104. 104
    Philippe Colson, Patrick Borentain, Anne Motte, Mireille Henry, Valérie Moal, Danielle Botta-Fridlund, Catherine Tamalet, René Gérolami, Clinical and virological significance of the co-existence of HBsAg and anti-HBs antibodies in hepatitis B chronic carriers, Virology, 2007, 367, 1, 30

    CrossRef

  105. 105
    H. L.-Y. CHAN, V. W.-S. WONG, C.-H. TSE, A. M.-L. CHIM, H.-Y. CHAN, G. L.-H. WONG, J. J.-Y. SUNG, Early virological suppression is associated with good maintained response to adefovir dipivoxil in lamivudine resistant chronic hepatitis B, Alimentary Pharmacology & Therapeutics, 2007, 25, 8
  106. 106
    H. Zhao, F. Kurbanov, M.-B. Wan, Y.-K. Yin, J.-Q. Niu, J.-L. Hou, L. Wei, G.-Q. Wang, Y. Tanaka, M. Mizokami, C.-W. Si, Genotype B and Younger Patient Age Associated with Better Response to Low-Dose Therapy: A Trial with Pegylated/Nonpegylated Interferon- -2b for Hepatitis B e Antigen--Positive Patients with Chronic Hepatitis B in China, Clinical Infectious Diseases, 2007, 44, 4, 541

    CrossRef

  107. 107
    Jay H. Hoofnagle, Edward Doo, T. Jake Liang, Russell Fleischer, Anna S.F. Lok, Management of hepatitis B: Summary of a clinical research workshop, Hepatology, 2007, 45, 4
  108. 108
    Anna Suk–Fong Lok, Navigating the Maze of Hepatitis B Treatments, Gastroenterology, 2007, 132, 4, 1586

    CrossRef

  109. 109
    Michael P. Curry, Nezam H. Afdhal, Prophylaxis against recurrent hepatitis B virus infection after liver transplantation, Current Hepatitis Reports, 2007, 6, 1, 30

    CrossRef

  110. 110
    Yun-Fan Liaw, Rescue therapy for lamivudine-resistant chronic hepatitis B: When and how?, Hepatology, 2007, 45, 2
  111. 111
    Fumitaka Suzuki, Norio Akuta, Yoshiyuki Suzuki, Hiromi Yatsuji, Hitomi Sezaki, Yasuji Arase, Yusuke Kawamura, Tetsuya Hosaka, Masahiro Kobayashi, Kenji Ikeda, Mariko Kobayashi, Sachiyo Watahiki, Hiromitsu Kumada, Selection of a virus strain resistant to entecavir in a nucleoside-naive patient with hepatitis B of genotype H, Journal of Clinical Virology, 2007, 39, 2, 149

    CrossRef

  112. 112
    Stéphanie Villet, Aurélie Ollivet, Christian Pichoud, Luc Barraud, Jean-Pierre Villeneuve, Christian Trépo, Fabien Zoulim, Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient, Journal of Hepatology, 2007, 46, 3, 531

    CrossRef

  113. 113
    Hiromi Yatsuji, Nobuhiko Hiraga, Nami Mori, Tsuyoshi Hatakeyama, Masataka Tsuge, Michio Imamura, Shoichi Takahashi, Yoshifumi Fujimoto, Hidenori Ochi, Hiromi Abe, Toshiro Maekawa, Fumitaka Suzuki, Hiromitsu Kumada, Kazuaki Chayama, Successful treatment of an entecavir-resistant hepatitis B virus variant, Journal of Medical Virology, 2007, 79, 12
  114. 114
    Maurizia Rossana Brunetto, Tailoring antiviral therapy in chronic hepatitis B patients with lamivudine resistance, Journal of Hepatology, 2007, 46, 5, 756

    CrossRef

  115. 115
    Futoshi Nagasaki, Hirofumi Niitsuma, Yoshiyuki Ueno, Jun Inoue, Takayuki Kogure, Koji Fukushima, Tooru Shimosegawa, The High Incidence of the Emergence of Entecavir-Resistant Mutants among Patients Infected with Lamivudine-Resistant Hepatitis B Virus, The Tohoku Journal of Experimental Medicine, 2007, 213, 2, 181

    CrossRef

  116. 116
    Jessica Tan, Anna SF Lok, Update on viral hepatitis: 2006, Current Opinion in Gastroenterology, 2007, 23, 3, 263

    CrossRef

  117. 117
    Fabien Zoulim, Hepatitis B virus resistance to entecavir in nucleoside naïve patients: Does it exist?, Hepatology, 2006, 44, 6
  118. 118
    Eugene R Schiff, Prevention of mortality from hepatitis B and hepatitis C, The Lancet, 2006, 368, 9539, 896

    CrossRef

  119. 119
    Masahito Minami, Takeshi Okanoue, Update of treatment for chronic hepatitis B using nucleos(t)ide analogues, Kanzo, 2006, 47, 11, 499

    CrossRef

  120. 120
    Anna S. F. Lok, Hepatitis B,
  121. 121
    Anna S. F. Lok, Francesco Negro, Hepatitis B and D,
  122. 122
    Hellan K. Kwon, Anna S.F. Lok, Treatment of Hepatitis B,